Stockreport

BiondVax Appoints CRO to Conduct Pivotal Clinical Efficacy Phase 3 Trial of Its Novel Universal Flu Vaccine Candidate

BiondVax Pharmaceuticals Ltd. - American Depositary Shares  (BVXV) 
US:NASDAQ Investor Relations: biondvax.com/investors